Response to: "Circular reasoning concerning red flags for predicting rituximab response in OCD"

Maike Gallwitz¹, Isa Lindqvist¹, Annica J Rasmusson¹, Simon Cervenka^{1

2}, Joachim Burman³, Janet L Cunningham^{4

5}

Affiliations

¹ Department of Medical Sciences, Clinical Psychiatry, Uppsala University, Uppsala, Sweden.
² Centre of Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institute and Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden.
³ Department of Medical Sciences, Translational Neurology, Uppsala University, Uppsala, Sweden.
⁴ Department of Medical Sciences, Clinical Psychiatry, Uppsala University, Uppsala, Sweden. janet.cunningham@uu.se.
⁵ Department of Neuroscience, Karolinska Institute, Stockholm, Sweden. janet.cunningham@uu.se.

Maike Gallwitz et al. Mol Psychiatry. 2025 Jul.

. 2025 Jul;30(7):3323-3324.

doi: 10.1038/s41380-025-03012-1. Epub 2025 Apr 28.

Maike Gallwitz¹, Isa Lindqvist¹, Annica J Rasmusson¹, Simon Cervenka^{1

2}, Joachim Burman³, Janet L Cunningham^{4

5}

¹ Department of Medical Sciences, Clinical Psychiatry, Uppsala University, Uppsala, Sweden.
² Centre of Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institute and Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden.
³ Department of Medical Sciences, Translational Neurology, Uppsala University, Uppsala, Sweden.
⁴ Department of Medical Sciences, Clinical Psychiatry, Uppsala University, Uppsala, Sweden. janet.cunningham@uu.se.
⁵ Department of Neuroscience, Karolinska Institute, Stockholm, Sweden. janet.cunningham@uu.se.

No abstract available

Conflict of interest statement

Competing interests: The authors declare no competing interests.

1. Bejerot S, Hietala AM, Soderbergh A, Humble MB. Circular reasoning concerning red flags for predicting rituximab response in OCD. Mol Psychiatry. 2025;30:1710–11. - PMC - PubMed
1. Gallwitz M, Lindqvist I, Mulder J, Rasmusson AJ, Larsson A, Husén E, et al. Three cases with chronic obsessive compulsive disorder report gains in wellbeing and function following rituximab treatment. Mol Psychiatry 2025;30:1396–1406. - PMC - PubMed
1. Syk M, Tornvind E, Gallwitz M, Fallmar D, Amandusson A, Rothkegel H, et al. An exploratory study of the damage markers NfL, GFAP, and t-Tau, in cerebrospinal fluid and other findings from a patient cohort enriched for suspected autoimmune psychiatric disease. Transl Psychiatry. 2024;14:304. - PMC - PubMed
1. Bejerot S, Sigra Stein S, Welin E, Eklund D, Hylen U, Humble MB. Rituximab as an adjunctive treatment for schizophrenia spectrum disorder or obsessive-compulsive disorder: two open-label pilot studies on treatment-resistant patients. J Psychiatr Res. 2023;158:319–29. - PubMed